Drug intelligence / Profile preview

Afecox S

Development stage
Unknown
Lead developer
Apostle Remedies
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Afecox S is a fixed-dose combination oral tablet containing the non-steroidal anti-inflammatory drug (NSAID) aceclofenac, the analgesic and antipyretic paracetamol (acetaminophen), and the proteolytic enzyme serratiopeptidase. Developed and marketed by Apostle Remedies, it is indicated for the relief of pain, swelling, and inflammation associated with various musculoskeletal and joint disorders, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, muscle strains, and post-operative recovery. Aceclofenac and paracetamol work synergistically to alleviate pain and reduce fever by inhibiting cyclooxygenase (COX) enzymes, thereby decreasing prostaglandin synthesis. Serratiopeptidase, a proteolytic enzyme, helps reduce edema and inflammation by breaking down abnormal proteins, such as fibrin, at the site of injury or inflammation.

Brand names
Afecox S
Other names
Aceclofenac + Paracetamol + Serratiopeptidase
02

Targets

BK (Bradykinin)Fibrin (Factor Ia)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Afecox S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afecox S.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call